|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.85 CNY | +2.96% |
|
+8.91% | +8.91% |
| 12-07 | Betta Pharmaceuticals's Four Drugs Placed on China's Insurance Drug List | MT |
| 11-02 | Betta Pharmaceuticals Gets Distribution Rights for Hemophilia Drug | MT |
| Capitalization | 21.28B 3.05B 2.61B 2.43B 2.27B 4.23B 275B 4.54B 28B 11.01B 132B 11.45B 11.21B 483B | P/E ratio 2025 * |
37.3x | P/E ratio 2026 * | 25.5x |
|---|---|---|---|---|---|
| Enterprise value | 22.68B 3.25B 2.79B 2.59B 2.42B 4.51B 293B 4.84B 29.84B 11.73B 140B 12.2B 11.95B 514B | EV / Sales 2025 * |
6.31x | EV / Sales 2026 * | 5.24x |
| Free-Float |
51.51% | Yield 2025 * |
0.71% | Yield 2026 * | 0.91% |
| 1 day | +2.96% | ||
| 1 week | +8.91% | ||
| Current month | +8.91% | ||
| 1 month | +5.67% | ||
| 3 months | -25.07% | ||
| 6 months | -11.90% | ||
| Current year | +8.91% |
| 1 week | 48.57 |  | 50.87 |
| 1 month | 45.25 | | 50.87 |
| Current year | 46.62 | | 50.87 |
| 1 year | 45.25 | | 79.8 |
| 3 years | 30.43 | | 79.8 |
| 5 years | 30.43 | | 143.59 |
| 10 years | 23.19 | | 160.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lie Ming Ding
CEO | Chief Executive Officer | 61 | 2013-08-22 |
Jian Xun Fan
DFI | Director of Finance/CFO | 54 | 2017-03-30 |
Mao Li
CTO | Chief Tech/Sci/R&D Officer | 69 | 2025-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yan Ki Wong
BRD | Director/Board Member | 54 | 2020-12-31 |
Lie Ming Ding
CHM | Chairman | 61 | 2013-08-22 |
Wei Wang
BRD | Director/Board Member | 59 | 2019-11-21 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -19.71% | 0.36% | 0 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.96% | +8.91% | -2.90% | -14.10% | 3.05B | |
| -0.72% | +6.05% | -7.15% | -33.47% | 66.64B | |
| -0.07% | +1.71% | +37.16% | +42.90% | 8.52B | |
| -0.49% | +1.77% | +9.81% | -12.38% | 8.51B | |
| +0.24% | +1.79% | +8.69% | +68.15% | 6.57B | |
| 0.00% | +0.44% | -15.45% | +116.69% | 5.71B | |
| -2.48% | -4.66% | +191.65% | +48.65% | 4.31B | |
| +0.49% | +3.97% | +37.00% | +32.58% | 2.94B | |
| -0.09% | +7.30% | +50.82% | +27.75% | 2.61B | |
| +0.76% | +4.20% | -3.18% | +15.48% | 2.05B | |
| Average | +0.28% | +1.72% | +30.64% | +29.22% | 11.09B | |
| Weighted average by Cap. | -0.36% | +4.27% | +8.53% | -4.42% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.59B 515M 441M 410M 383M 715M 46.46B 767M 4.73B 1.86B 22.23B 1.93B 1.89B 81.49B | 4.31B 618M 529M 492M 458M 857M 55.66B 919M 5.67B 2.23B 26.63B 2.32B 2.27B 97.63B |
| Net income | 571M 81.93M 70.16M 65.24M 60.83M 114M 7.38B 122M 752M 295M 3.53B 307M 301M 12.95B | 812M 116M 99.67M 92.69M 86.42M 161M 10.49B 173M 1.07B 420M 5.02B 437M 428M 18.4B |
| Net Debt | 1.4B 201M 172M 160M 149M 278M 18.08B 299M 1.84B 724M 8.65B 752M 737M 31.72B | 1.28B 184M 158M 147M 137M 255M 16.59B 274M 1.69B 664M 7.94B 690M 676M 29.1B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-12 | 50.59 ¥ | -0.51% | 9,822,624 |
| 26-01-09 | 50.85 ¥ | +2.96% | 10,392,020 |
| 26-01-08 | 49.39 ¥ | -0.38% | 7,926,250 |
| 26-01-07 | 49.58 ¥ | +0.47% | 8,833,251 |
| 26-01-06 | 49.35 ¥ | +0.92% | 6,762,532 |
End-of-day quote Shenzhen S.E., January 08, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300558 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition